Janux Therapeutics (JANX) Other Non-Current Assets (2021 - 2026)

Janux Therapeutics (JANX) has 6 years of Other Non-Current Assets data on file, last reported at $3.9 million in Q1 2026.

• On a quarterly basis, Other Non-Current Assets rose 41.26% year-over-year to $3.9 million in Q1 2026; TTM through Mar 2026 was $3.9 million, a 41.26% increase from a year earlier, with the FY2025 full-year figure at $816000.0, changed 0.0% from the prior year.
• Other Non-Current Assets for Q1 2026 stood at $3.9 million, up from $816000.0 in the prior quarter.
• Over the last five years, Other Non-Current Assets for JANX reached as high as $3.9 million in Q1 2026 and fell as low as $816000.0 in Q1 2022.
• Historically, Other Non-Current Assets has averaged $1.6 million across 5 years, with a median of $816000.0 in 2022.
• Across the five-year window, Other Non-Current Assets jumped 482.86% in 2022 and slumped 67.48% in 2024, its largest moves.
• Year by year, Other Non-Current Assets stood at $816000.0 in 2022, then jumped by 207.48% to $2.5 million in 2023, then slumped by 67.48% to $816000.0 in 2024, then changed by 0.0% to $816000.0 in 2025, then soared by 383.33% to $3.9 million in 2026.
• Per Business Quant data, the three most recent Other Non-Current Assets figures were $3.9 million in Q1 2026, $816000.0 in Q4 2025, and $816000.0 in Q3 2025.